Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Exp Biol Med (Maywood) ; 239(2): 225-31, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24419461

ABSTRACT

Pneumococcal meningitis is a relevant clinical disease characterized by an intense inflammatory reaction into the subarachnoid and ventricular spaces, leading to blood-brain barrier breakdown, hearing loss, and cognitive impairment. Matrix metalloproteinases (MMPs) are capable of degrading components of the basal laminin, thus contributing to BBB damage and neuronal injury. In the present study, we evaluated the effects of MMP-2, MMP-9, and MMP-2/9 inhibitors on BBB integrity, learning, and memory in Wistar rats subjected to pneumococcal meningitis. The animals underwent a magna cistern tap and received either 10 µL sterile saline as a placebo or an equivalent volume of a Streptococcus pneumoniae suspension at a concentration of 5 × 10(9)cfu/mL. The rats were randomized into different groups that received adjuvant treatment with MMP-2, MMP-9 or MMP-2/9 inhibitors. The BBB integrity was evaluated, and the animals were habituated to open-field and object recognition tasks 10 days after meningitis induction. Adjuvant treatments with inhibitors of MMP-2 or MMP-2/9 prevented BBB breakdown in the hippocampus, and treatments with inhibitors of MMP-2, MMP-9 or MMP-2/9 prevented BBB breakdown in the cortex. Ten days after meningitis induction, the animals that received adjuvant treatment with the inhibitor of MMP-2/9 demonstrated that animals habituated to the open-field task faster and enhanced memory during short-term and long-term retention test sessions in the object recognition task. Further investigation is necessary to provide support for MMP inhibitors as an alternative treatment for bacterial meningitis; however, these findings suggest that the meningitis model could be a good research tool for studying the biological mechanisms involved in the behavioral alterations associated with pneumococcal meningitis.


Subject(s)
Cognition Disorders/prevention & control , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinase Inhibitors/therapeutic use , Meningitis, Pneumococcal/drug therapy , Animals , Blood-Brain Barrier/microbiology , Blood-Brain Barrier/physiopathology , Cognition Disorders/etiology , Disease Models, Animal , Hippocampus/drug effects , Hippocampus/pathology , Learning/drug effects , Memory/drug effects , Meningitis, Pneumococcal/complications , Meningitis, Pneumococcal/metabolism , Rats , Rats, Wistar , Streptococcus pneumoniae
2.
Metab Brain Dis ; 27(4): 587-93, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22592569

ABSTRACT

Pneumococcal meningitis is associated with the highest fatality case ratios in the world. Most of patients that survive present neurologic sequelae at later times as well as biochemicals alterations such as oxidative stress in both earlier and later times after central nervous system infection. In this context, we evaluated the effect of antioxidant treatment on memory and oxidative parameters in the hippocampus of meningitis survivor rats 10 days after infection. To this aim, the animals underwent a magna cistern tap receiving either 10 µL sterile saline as a placebo or an equivalent volume of a Streptococcus pneumoniae suspension at the concentration 5x10(9) cfu/mL. The animals submitted to meningitis were divided into the following groups: 1) treated with antibiotic, 2) treated with basic support plus N-acetylcysteine, 3) treated with basic support plus deferoxamine, 4) treated with basic support plus N-acetylcysteine and deferoxamine, or 5) treated with N-acetylcysteine plus deferoxamine. Ten days after meningitis, the animals underwent inhibitory avoidance and habituation to an open field tasks and, immediately after, were assessed for oxidative damage in the hippocampus and cortex. The meningitis group showed significantly decreased performance in latency retention compared with the sham group in the inhibitory avoidance task. In the open-field task, the meningitis group presented memory impairment after meningitis. All these memory impairments were prevented by N-acetylcysteine plus deferoxamine with or without basic support and its isolate use. In addition, there was an increase of lipid phosphorylation in cortex and hippocampus and all the combined antioxidants attenuated lipid phosphorylation in both structures. On the other hand, there was an increase of protein phosphorylation in cortex and N-acetylcysteine plus deferoxamine with or without basic support prevented it. Thus, we hypothesize that oxidative stress may be related to cognitive impairment in pneumococcal meningitis.


Subject(s)
Antioxidants/therapeutic use , Cognition Disorders/etiology , Cognition Disorders/prevention & control , Meningitis, Pneumococcal/drug therapy , Meningitis, Pneumococcal/psychology , Oxidative Stress/drug effects , Acetylcysteine/therapeutic use , Animals , Avoidance Learning/drug effects , Behavior, Animal/drug effects , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Deferoxamine/therapeutic use , Free Radical Scavengers/therapeutic use , Habituation, Psychophysiologic/drug effects , Hippocampus/drug effects , Hippocampus/metabolism , Lipid Peroxidation/drug effects , Male , Memory/drug effects , Rats , Rats, Wistar , Survivors , Thiobarbituric Acid Reactive Substances/metabolism
3.
Microbiol Immunol ; 56(3): 191-4, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22188584

ABSTRACT

Pneumococcal meningitis is a life-threatening disease characterized by acute purulent infection of the meninges causing neuronal injury, cortical necrosis and hippocampal apoptosis. Cholinergic neurons and their projections are extensively distributed throughout the central nervous system. The aim of this study was to assess acetylcholinesterase activity in the rat brain after pneumococcal meningitis. In the hippocampus, frontal cortex and cerebrospinal fluid, acetylcholinesterase activity was found to be increased at 6, 12, 24, 48 and 96 hr without antibiotic treatment, and at 48 and 96 hr with antibiotic treatment. Our data suggest that acetylcholinesterase activity could be related to neuronal damage induced by pneumococcal meningitis.


Subject(s)
Acetylcholinesterase/biosynthesis , Brain/enzymology , Brain/microbiology , Meningitis, Pneumococcal/pathology , Animals , Brain/pathology , Cerebral Cortex/enzymology , Cerebral Cortex/pathology , Cerebrospinal Fluid/enzymology , Disease Models, Animal , GPI-Linked Proteins/biosynthesis , Hippocampus/enzymology , Hippocampus/pathology , Rats , Time Factors
4.
J Neural Transm (Vienna) ; 117(7): 819-26, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20559668

ABSTRACT

Alterations in hippocampus frequently occur following bacterial meningitis, despite antibiotic treatment. We investigated the cognitive performance in rats submitted to bacterial meningitis after 10, 30, and 60 days. To this aim, we utilized male Wistar rats submitted to either sham (control) or meningitis by Streptococcus pneumoniae, and followed by the initiation of the antibiotic treatment at 16 h after inoculation. The animals underwent six behavioral tasks 10, 30 and 60 days after surgery. We demonstrated that some of the learning and memory impairment, demonstrated 10 days after the induction of meningitis, persists up to 30 days, but not 60 days after induction.


Subject(s)
Cognition , Meningitis, Pneumococcal/psychology , Recovery of Function , Animals , Anti-Bacterial Agents/therapeutic use , Avoidance Learning , Depression , Habituation, Psychophysiologic , Male , Maze Learning , Meningitis, Pneumococcal/drug therapy , Neuropsychological Tests , Rats , Rats, Wistar , Recognition, Psychology , Time Factors
5.
Clin Chem Lab Med ; 40(5): 452-5, 2002 May.
Article in English | MEDLINE | ID: mdl-12113286

ABSTRACT

Individuals infected with the human immunodeficiency virus (HIV-1) present with decreased CD4, a progressive increase in viral load, compromised cell immune defense, and hematologic alterations. The aim of this study was to assess the serum viral load, CD4, CD8, lymphocyte count and hematocrit at the beginning of antiretroviral therapy in individuals who were supplemented with N-acetylcysteine (NAC). Twenty volunteers participated in this double-blind, placebo-controlled 180-day study. Ten participants received 600 mg of NAC per day (NAC group) and the other ten serving as a control group received placebo. The above mentioned parameters were determined before treatment, and after 60, 120 and 180 days. In NAC-treated patients hematocrit remained stable and an increase in CD4 cell count took place earlier than that in the control group.


Subject(s)
Acetylcysteine/administration & dosage , Anti-HIV Agents/administration & dosage , CD4-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/drug effects , HIV Infections/drug therapy , Viral Load , Acetylcysteine/pharmacology , Anti-HIV Agents/pharmacology , CD4-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/cytology , Double-Blind Method , Drug Therapy, Combination , Female , HIV Infections/blood , HIV Infections/immunology , Hematocrit , Humans , Lymphocyte Count , Male
6.
Clin Chem Lab Med ; 40(5): 456-9, 2002 May.
Article in English | MEDLINE | ID: mdl-12113287

ABSTRACT

In HIV-infected patients, an increase in the production of oxygen-reactive species (ROS) is observed, with a consequent reduction of plasma levels of antioxidants such as alpha-tocopherol. The nuclear transcription factor-kappaB (NF-kappaB) is activated by a prooxidant state in the infected T cells through the release of its inhibitory subunit I-kappaB. The aim of the present work was to evaluate the behavior of hematological parameters and markers of anemia in HIV-infected patients who underwent antiretroviral therapy associated with 800 mg/day alpha-tocopherol supplementation. Blood samples were collected from supplemented (n=9) and not-supplemented (n=9) HIV-seropositive patients (n=18). We observed a decreased viral load in the alpha-tocopherol-supplemented group (p<0.05); other changes, such as an increase in the CD4/CD8 ratio, in the hematocrit and in the hemoglobin concentration were also observed, though lacking statistical significance. We conclude that antiretroviral therapy in association with alpha-tocopherol (800 mg/day) supplementation is more effective in reducing viral load levels and also, possibly, in recovering other hematological parameters after a 60-day period of use.


Subject(s)
Anti-HIV Agents/administration & dosage , Antioxidants/administration & dosage , HIV Infections/drug therapy , alpha-Tocopherol/administration & dosage , Anemia/blood , Anemia/diagnosis , Anemia/drug therapy , CD4-CD8 Ratio , Double-Blind Method , Drug Therapy, Combination , Female , HIV Infections/blood , HIV Infections/complications , Hematocrit , Hemoglobins/drug effects , Hemoglobins/metabolism , Humans , Kinetics , Male , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL